The pharmaceutical field is experiencing a significant shift in glucose treatment with the arrival of GLP-1 transdermal devices. These revolutionary delivery systems offer a likely convenient option to subcutaneous injections for individuals dealing with type 2 diabetes. By avoiding the necessity